Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Precision BioSciences (DTIL) Misses Q2 EPS by 4c, Revenues Miss
August 13, 2020 7:06 AM EDTPrecision BioSciences (NASDAQ: DTIL) reported Q2 EPS of ($0.63), $0.04 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $1.08 million versus the consensus estimate of $4.39 million.
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple MyelomaPBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim Data... More